Skip to main content
Psychedex
Sources
41
11 strong · 24 moderate · 6 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
99
68verified13partial18inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
Apr 28, 2026 · pipeline-v5
Values approved
134/134 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold25 mg25 mgmedium
Low25–75 mg25–75 mgmedium
Common75–300 mg75–300 mgmedium
Strong300–600 mg300–600 mgmedium
Heavy600+ mg600+ mgmedium
Editorial

Therapeutic dosing range (75-600 mg) from FDA-approved labeling and clinical trials (Ben-Menachem 2004, Freynhagen et al. 2005, Crofford et al. 2005). Threshold and light doses inferred from sub-therapeutic dosing. The moderate range encompasses standard therapeutic dosing for most indications. Heavy threshold (600+ mg) marks the transition to supratherapeutic/recreational territory where doses of 1000-2000+ mg are reported (Schifano 2014). Bioavailability ≥90% from published PK data.

Reasoning

Therapeutic dosing range (75-600 mg) from FDA-approved labeling and clinical trials (Ben-Menachem 2004, Freynhagen et al. 2005, Crofford et al. 2005). Threshold and light doses inferred from sub-therapeutic dosing. The moderate range encompasses standard therapeutic dosing for most indications. Heavy threshold (600+ mg) marks the transition to supratherapeutic/recreational territory where doses of 1000-2000+ mg are reported (Schifano 2014). Bioavailability ≥90% from published PK data.

Evidence basis: controlled_human_study

rectal

Predates provenance tracking — no derivation record for this dataset

FieldPublishedAI ProposedConfidence
Threshold40 mgno record
Low40–200 mgno record
Common200–450 mgno record
Strong450–600 mgno record
Heavy600+ mgno record
Editorial

Carried forward from Curiosity v1 seed version during v1 history consolidation (2026-06-04).

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace15–30 minutes15–30 minutesmedium
Editorial

Tmax ~1 hour (Ben-Menachem 2004). First perceptible effects expected before peak plasma concentration. Onset inferred from clinical onset-of-effect data and Tmax.

Reasoning

Tmax ~1 hour (Ben-Menachem 2004). First perceptible effects expected before peak plasma concentration. Onset inferred from clinical onset-of-effect data and Tmax.

Evidence basis: controlled_human_study

Come uptrace30–45 minutes30–45 minutesmedium
Editorial

Building from first effects toward peak. Tmax ~1 hour sets the anchor for approaching peak intensity.

Reasoning

Building from first effects toward peak. Tmax ~1 hour sets the anchor for approaching peak intensity.

Evidence basis: controlled_human_study

Peaktrace1.5–3 hours1.5–3 hoursmedium
Editorial

Peak subjective intensity around Tmax (~1 hour) extending through early distribution phase. Half-life of 6.3 hours means substantial plasma levels persist for several hours.

Reasoning

Peak subjective intensity around Tmax (~1 hour) extending through early distribution phase. Half-life of 6.3 hours means substantial plasma levels persist for several hours.

Evidence basis: controlled_human_study

Offsettrace2–4 hours2–4 hoursmedium
Editorial

Declining intensity from peak through approximately 2 half-lives of elimination. Subjective offset corresponds to declining plasma levels.

Reasoning

Declining intensity from peak through approximately 2 half-lives of elimination. Subjective offset corresponds to declining plasma levels.

Evidence basis: controlled_human_study

Totaltrace5–8 hours5–8 hoursmedium
Editorial

Total subjective experience duration estimated from PK profile (t1/2 6.3 hours) and clinical effect duration reports. Covers onset through offset of perceptible effects, not residual subclinical activity.

Reasoning

Total subjective experience duration estimated from PK profile (t1/2 6.3 hours) and clinical effect duration reports. Covers onset through offset of perceptible effects, not residual subclinical activity.

Evidence basis: controlled_human_study

After effectstrace2–6 hours2–6 hourslow
Editorial

Residual sedation, mild anxiolytic aftereffect, and subtle cognitive dulling may persist beyond subjective experience. Estimated from pharmacological half-life and clinical reports of next-day drowsiness.

Reasoning

Residual sedation, mild anxiolytic aftereffect, and subtle cognitive dulling may persist beyond subjective experience. Estimated from pharmacological half-life and clinical reports of next-day drowsiness.

Evidence basis: expert_opinion

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutelowlowmedium
Chronicmoderatemoderatemedium
Organs Affectedcentral nervous system, kidney, reproductive system, musculoskeletalcentral nervous system, kidney, reproductive system, musculoskeletalmedium
Editorial

Acute toxicity classified as low based on wide therapeutic window, no reported single-agent fatalities at therapeutic doses, and systematic safety review data (Ogawa et al. 2012, Frampton 2014). Chronic toxicity classified as moderate: animal data show gonadotoxicity and musculoskeletal effects at high doses (Taha et al. 2020, Reyes Fernandez et al. 2022), but human evidence for chronic organ damage at therapeutic doses is limited — downgraded from high because animal doses greatly exceed human therapeutic exposure.

Reasoning

Acute toxicity classified as low based on wide therapeutic window, no reported single-agent fatalities at therapeutic doses, and systematic safety review data (Ogawa et al. 2012, Frampton 2014). Chronic toxicity classified as moderate: animal data show gonadotoxicity and musculoskeletal effects at high doses (Taha et al. 2020, Reyes Fernandez et al. 2022), but human evidence for chronic organ damage at therapeutic doses is limited — downgraded from high because animal doses greatly exceed human therapeutic exposure.

Evidence basis: systematic_review

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalmoderatemoderatehigh
Psychologicalmoderatemoderatehigh
Compulsive Redosingmoderatemoderatehigh
Dose Escalationhighhighhigh
Editorial

Physical dependence at therapeutic doses documented in multiple case series (Ishikawa et al. 2021, Papanna et al. 2021, Aldemir et al. 2015). Dose escalation tendency rated high based on pharmacovigilance data showing recreational doses 3-20x therapeutic (Schifano 2014) and pregabalin becoming the #1 forged prescription drug in France (Tambon et al. 2021). Primary abuse without prior SUD confirmed in French data.

Reasoning

Physical dependence at therapeutic doses documented in multiple case series (Ishikawa et al. 2021, Papanna et al. 2021, Aldemir et al. 2015). Dose escalation tendency rated high based on pharmacovigilance data showing recreational doses 3-20x therapeutic (Schifano 2014) and pregabalin becoming the #1 forged prescription drug in France (Tambon et al. 2021). Primary abuse without prior SUD confirmed in French data.

Evidence basis: published_case_series

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitymoderatemoderatemedium
Symptomsinsomnia, rebound anxiety, agitation, nausea, diaphoresis, headache, tremor, seizuresinsomnia, rebound anxiety, agitation, nausea, diaphoresis, headache, tremor, seizuresmedium
FatalNoNomedium
Medical SupervisionRequiredRequiredmedium
Editorial

Withdrawal documented at therapeutic doses after 2 months of use (Ishikawa et al. 2021). Seizures reported in severe cases, warranting medical supervision. Diazepam cross-taper protocol used in inpatient settings (Papanna et al. 2021). Gradual taper over at least 1 week recommended (Frampton 2014).

Reasoning

Withdrawal documented at therapeutic doses after 2 months of use (Ishikawa et al. 2021). Seizures reported in severe cases, warranting medical supervision. Diazepam cross-taper protocol used in inpatient settings (Papanna et al. 2021). Gradual taper over at least 1 week recommended (Frampton 2014).

Evidence basis: published_case_series

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupmoderatemoderatelow
Half-life——low
Full Reset——low
Cross-tolerancesgabapentingabapentinlow
Editorial

Tolerance buildup rated as moderate based on clinical observation that sedation/dizziness tolerance develops within weeks while therapeutic effects may persist longer. No published study establishes precise tolerance half-life or full reset values. Cross-tolerance with gabapentin inferred from shared α₂δ mechanism.

Reasoning

Tolerance buildup rated as moderate based on clinical observation that sedation/dizziness tolerance develops within weeks while therapeutic effects may persist longer. No published study establishes precise tolerance half-life or full reset values. Cross-tolerance with gabapentin inferred from shared α₂δ mechanism.

Evidence basis: expert_opinion

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
respiratory concurrent opioid usetraceabsoluteabsolutehigh
Editorial

Documented in multiple pharmacovigilance databases (Evoy et al. 2021, Lyndon et al. 2017, Torrance et al. 2020, Tambon et al. 2021). Animal mechanistic data from Hiranita et al. 2025.

Reasoning

Documented in multiple pharmacovigilance databases (Evoy et al. 2021, Lyndon et al. 2017, Torrance et al. 2020, Tambon et al. 2021). Animal mechanistic data from Hiranita et al. 2025.

renal severe renal impairmenttraceabsoluteabsolutehigh
Editorial

Published PK study in renal impairment (Randinitis et al. 2003) establishing dose-clearance proportionality and mandatory dose reduction guidelines.

Reasoning

Published PK study in renal impairment (Randinitis et al. 2003) establishing dose-clearance proportionality and mandatory dose reduction guidelines.

pregnancy breastfeeding pregnancytraceabsoluteabsolutehigh
Editorial

Animal teratogenicity data and human cohort study (Patorno et al. 2017) assessing first-trimester exposure risk.

Reasoning

Animal teratogenicity data and human cohort study (Patorno et al. 2017) assessing first-trimester exposure risk.

psychiatric substance use disorder historytracerelativerelativehigh
Editorial

German regulatory database (Gahr et al. 2013), French addictovigilance data (Tambon et al. 2021), and misuse review (Schifano 2014) document elevated risk in SUD populations.

Reasoning

German regulatory database (Gahr et al. 2013), French addictovigilance data (Tambon et al. 2021), and misuse review (Schifano 2014) document elevated risk in SUD populations.

respiratory concurrent benzodiazepine or Z-drug usetracerelativerelativehigh
Editorial

Fatal case report (Shintani-Ishida et al. 2024) and pharmacodynamic reasoning for additive respiratory depression.

Reasoning

Fatal case report (Shintani-Ishida et al. 2024) and pharmacodynamic reasoning for additive respiratory depression.

cardiovascular heart failuretracerelativerelativemedium
Editorial

Peripheral edema incidence from systematic safety review (Ogawa et al. 2012). Heart failure contraindication based on class effect and prescribing information.

Reasoning

Peripheral edema incidence from systematic safety review (Ogawa et al. 2012). Heart failure contraindication based on class effect and prescribing information.

other concurrent alcohol usetracerelativerelativemedium
Editorial

Pharmacodynamic reasoning for additive CNS depression. Standard prescribing guidance.

Reasoning

Pharmacodynamic reasoning for additive CNS depression. Standard prescribing guidance.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace900–1800 sec(i=0.05)900–1800 sec(i=0.05)medium
Editorial

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Reasoning

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Come uptrace1800–2700 sec(i=0.30)1800–2700 sec(i=0.30)medium
Editorial

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Reasoning

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Peaktrace5400–10800 sec(i=1.00)5400–10800 sec(i=1.00)medium
Editorial

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Reasoning

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Plateautrace3600–7200 sec(i=0.50)3600–7200 sec(i=0.50)medium
Editorial

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Reasoning

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Resolutiontrace3600–7200 sec(i=0.20)3600–7200 sec(i=0.20)medium
Editorial

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Reasoning

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Afterglowtrace7200–14400 sec(i=0.05)7200–14400 sec(i=0.05)medium
Editorial

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Reasoning

Timeline based on published PK data: Tmax ~1 hour, t1/2 6.3 hours (Ben-Menachem 2004). Onset and come-up durations inferred from Tmax. Peak and plateau durations derived from pharmacokinetic profile and clinical trial duration-of-effect reports. No published subjective experience timeline studies exist for pregabalin; timing estimates integrate PK parameters with clinical effect onset data from GAD trials (Frampton 2014).

Dose Tier Summaries

thresholdtrace
medium

At threshold doses, effects are subtle and often indistinguishable from placebo in controlled settings. A mild sense of relaxation or anxiolysis may be perceived, with slight mood elevation and reduced background anxiety. Physical tension may ease marginally. No meaningful sedation, dizziness, or cognitive impairment occurs at this level. Sleep architecture is unaffected. Functional impairment is negligible, and the experience does not interfere with daily activities.

Editorial

Therapeutic dosing begins at 75 mg. Threshold effects inferred from sub-therapeutic dose reports and clinical titration data. No published controlled studies at sub-therapeutic doses.

Reasoning

Therapeutic dosing begins at 75 mg. Threshold effects inferred from sub-therapeutic dose reports and clinical titration data. No published controlled studies at sub-therapeutic doses.

Evidence basis: community_consensus_large

lighttrace
medium

Mild anxiolysis and muscle relaxation become noticeable. A gentle sense of calm settles over the experience, with reduced worry and somatic tension. Mood may lift modestly, and social anxiety diminishes. Some users report enhanced appreciation of music and slight emotional warmth. Physically, mild dizziness and light-headedness may emerge, particularly in opioid-naive individuals. Slight drowsiness is possible but not pronounced. Coordination is minimally affected. Functional impairment is mild. Driving and complex tasks remain feasible for most individuals, though caution is warranted during initial exposure.

Editorial

Based on clinical dosing data at 75-150 mg (starting therapeutic range). Adverse effect incidence data from Ogawa et al. 2012 and Freynhagen et al. 2005 inform the physical effects.

Reasoning

Based on clinical dosing data at 75-150 mg (starting therapeutic range). Adverse effect incidence data from Ogawa et al. 2012 and Freynhagen et al. 2005 inform the physical effects.

Evidence basis: controlled_human_study

commontrace
high

Pronounced anxiolysis and sedation characterize this range, which encompasses standard therapeutic dosing for most approved indications. Anxiety reduction is broad-spectrum, affecting both psychic worry and somatic tension. Analgesia becomes clinically meaningful in neuropathic pain conditions. Mood elevation is consistent, and social fluency may increase. Sleep quality improves significantly. Dizziness (23-25% incidence), somnolence (13-15% incidence), and mild peripheral edema emerge as common adverse effects. Cognitive processing slows, and psychomotor performance declines measurably. Weight gain may begin with sustained use. Functional impairment is moderate. Driving ability is compromised, particularly during dose titration. Sleep onset is facilitated, and daytime drowsiness may persist for several hours after dosing.

Editorial

Corresponds to standard therapeutic dosing (150-300 mg/day). Adverse effect incidence rates from systematic safety review (Ogawa et al. 2012). Efficacy data from multiple RCTs.

Reasoning

Corresponds to standard therapeutic dosing (150-300 mg/day). Adverse effect incidence rates from systematic safety review (Ogawa et al. 2012). Efficacy data from multiple RCTs.

Evidence basis: controlled_human_study

strongtrace
medium

At the upper therapeutic range, sedation deepens substantially and euphoria begins to emerge — the transition zone between therapeutic use and recreational experience. Anxiolysis is maximal. Analgesia reaches peak clinical efficacy. A distinct sense of bodily relaxation and physical comfort pervades the experience. Emotional blunting may occur alongside the anxiolysis. Some users report a dissociative quality — feeling "wrapped in cotton" or detached from concerns. Dizziness becomes pronounced (up to 31% incidence), somnolence is common, and peripheral edema and weight gain are more likely. Blurred vision and diplopia may occur. Cognitive impairment is significant: word-finding difficulty, impaired short-term memory, and reduced reaction time. Driving and operating machinery are unsafe at this dose range. Sleep is strongly promoted. The experience occupies approximately 5-8 hours of active effects with residual sedation persisting longer.

Editorial

Corresponds to 300-600 mg/day (upper therapeutic to early supratherapeutic). Euphoria emergence at higher doses documented in misuse literature (Schifano 2014, Evoy et al. 2021). Adverse effect data from clinical trials.

Reasoning

Corresponds to 300-600 mg/day (upper therapeutic to early supratherapeutic). Euphoria emergence at higher doses documented in misuse literature (Schifano 2014, Evoy et al. 2021). Adverse effect data from clinical trials.

Evidence basis: controlled_human_study

heavytrace
low

At doses exceeding the maximum recommended therapeutic range, pregabalin produces overt euphoria, pronounced disinhibition, and a subjective "high" that recreational users describe as comparable to other CNS depressants. Bodily lightness, tactile euphoria, emotional expansiveness, and marked social disinhibition are reported. Users describe the compound as a "valid substitute for most common illicit drugs" at these levels. Perceptual changes including auditory and visual enhancement are anecdotally reported but not confirmed by controlled studies. Physical effects include profound sedation, severe dizziness, ataxia, slurred speech, and significant psychomotor impairment. Nausea and vomiting may occur. Respiratory depression risk increases substantially when combined with other CNS depressants. Functional impairment is severe. These doses carry significant overdose risk, particularly in polydrug contexts. Sleep is virtually guaranteed, and residual effects may persist well into the following day. The risk of dependence escalates rapidly with repeated use at this level.

Editorial

Based on pharmacovigilance and misuse literature: recreational users take 3-20x therapeutic doses (Schifano 2014). Euphoria, disinhibition documented in case reports and surveys (Evoy et al. 2021). Subjective effects not confirmed by controlled studies. Perceptual effects flagged as community-reported only.

Reasoning

Based on pharmacovigilance and misuse literature: recreational users take 3-20x therapeutic doses (Schifano 2014). Euphoria, disinhibition documented in case reports and surveys (Evoy et al. 2021). Subjective effects not confirmed by controlled studies. Perceptual effects flagged as community-reported only.

Evidence basis: published_case_series

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

11 strong · 24 moderate · 6 weak
  1. [1]
    moderate
    Pregabalin pharmacology and its relevance to clinical practice.
    Ben-Menachem E · 2004 · Epilepsia
    pubmed 1531551111 claims checked5 verified1 partial5 inconclusive
  2. [2]
    moderate
    Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications.
    Kawczak P, Feszak I, Bączek T · 2024 · Biomedicines
    doi.org/10.3390/biomedicines12092021pubmed 393355352 claims checked1 verified1 partial
  3. [3]
    moderate
    Pregabalin: a review of its use in adults with generalized anxiety disorder.
    Frampton JE · 2014 · CNS Drugs
    doi.org/10.1007/s40263-014-0192-0pubmed 251498637 claims checked5 verified1 partial1 inconclusive
  4. [4]
    weak
    Reclassification of pregabalin and gabapentin to Schedule 3 drugs from 1 April 2019
    2019
    linkno claims checked
  5. [5]
    moderate
    Alpha2delta subunit voltage-gated calcium channel ligands: Ki values and anti-allodynic effects comparison.
    Lynch JJ, Honore P, Anderson DJ, et al. · 2006 · Pain
    pubmed 167810714 claims checked3 verified1 partial
  6. [6]
    moderate
    The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin.
    Bauer CS, Nieto-Rostro M, Rahman W, et al. · 2009 · Journal of Neuroscience
    doi.org/10.1523/jneurosci.0356-09.2009pubmed 193396036 claims checked5 verified1 partial
  7. [7]
    moderate
    Misuse and abuse of pregabalin and gabapentin: cause for concern?
    Schifano F · 2014 · CNS Drugs
    doi.org/10.1007/s40263-014-0164-4pubmed 247604364 claims checked3 verified1 inconclusive
  8. [8]
    moderate
    Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance.
    Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M · 2021 · Frontiers in Psychiatry
    doi.org/10.3389/fpsyt.2021.639780pubmed 336133454 claims checked1 verified1 partial2 inconclusive
  9. [9]
    weak
    Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review.
    Ishikawa H, Takeshima M, Ishikawa H, Ayabe N, Ohta H, Mishima K · 2021 · Neuropsychopharmacology Reports
    doi.org/10.1002/npr2.12195pubmed 343823804 claims checked3 verified1 partial
  10. [10]
    weak
    Fatal pregabalin poisoning in Japan: A case report.
    Shintani-Ishida K, Kawamoto M, Kondo H, Onoe T, Ikegaya H · 2024 · Legal Medicine (Tokyo)
    doi.org/10.1016/j.legalmed.2024.102522pubmed 391910474 claims checked3 verified1 inconclusive
  11. [11]
    weak
    Pregabalin (Lyrica) FDA Approval History
    2024
    linkno claims checked
  12. [12]
    weak
    Placement of pregabalin into Schedule V. Final rule
    2005
    pubmed 160500511 claim checked1 inconclusive
  13. [13]
    moderate
    Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland.
    Torrance N, Veluchamy A, Zhou Y, et al. · 2020 · British Journal of Anaesthesia
    doi.org/10.1016/j.bja.2020.05.017pubmed 325715684 claims checked4 verified
  14. [14]
    moderate
    Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study.
    Ashworth J, Bajpai R, Müller S, Bailey J, Helliwell T · 2023 · The Lancet Regional Health - Europe
    doi.org/10.1016/j.lanepe.2022.100579pubmed 370698522 claims checked2 partial
  15. [15]
    moderate
    A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.
    Chiappini S, Schifano F · 2016 · CNS Drugs
    doi.org/10.1007/s40263-016-0359-ypubmed 273123202 claims checked2 verified
  16. [16]
    moderate
    Neuronal alpha2delta proteins and brain disorders.
    Ablinger C, Geisler SM, Stanika RI, Klein CT, Obermair GJ · 2020 · Pflügers Archiv - European Journal of Physiology
    doi.org/10.1007/s00424-020-02420-2pubmed 326078092 claims checked1 verified1 inconclusive
  17. [17]
    moderate
    Pathophysiological Roles of Auxiliary Calcium Channel Alpha2delta Subunits.
    Hessenberger M, Haddad S, Obermair GJ · 2023 · Handbook of Experimental Pharmacology
    doi.org/10.1007/164_2022_630pubmed 365986092 claims checked1 verified1 partial
  18. [18]
    moderate
    Analgesia with Gabapentin and Pregabalin May Involve N-Methyl-d-Aspartate Receptors, Neurexins, and Thrombospondins.
    Taylor CP, Harris EW · 2020 · Journal of Pharmacology and Experimental Therapeutics
    doi.org/10.1124/jpet.120.266056pubmed 323217432 claims checked2 verified
  19. [19]
    moderate
    Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
    Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN · 2003 · Journal of Clinical Pharmacology
    pubmed 126383964 claims checked3 verified1 partial
  20. [20]
    moderate
    Effects of Gabapentin and Pregabalin on Calcium Homeostasis: Implications for Physical Rehabilitation of Musculoskeletal Tissues.
    Reyes Fernandez PC, Wright CS, Warden SJ, Hum J, Farach-Carson MC, Thompson WR · 2022 · Current Osteoporosis Reports
    doi.org/10.1007/s11914-022-00750-xpubmed 361495921 claim checked1 verified
  21. [21]
    moderate
    Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability.
    Evoy KE, Peckham AM, Covvey JR, Tidgewell KJ · 2021 · Journal of Clinical Pharmacology
    doi.org/10.1002/jcph.1833pubmed 343965495 claims checked5 verified
  22. [22]
    strong
    Pharmacokinetics of a New, Once-Daily, Sustained-release Pregabalin Tablet in Healthy Male Volunteers.
    Moon SJ, Jeon JY, Lim Y, An T, Jang SB, Kim S, Na WS, Lee SY, Kim MG · 2021 · Clinical Therapeutics
    doi.org/10.1016/j.clinthera.2021.06.010pubmed 342569641 claim checked1 inconclusive
  23. [23]
    strong
    Pregabalin for neuropathic pain in adults.
    Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA · 2019 · Cochrane Database of Systematic Reviews
    doi.org/10.1002/14651858.cd007076.pub3pubmed 306731201 claim checked1 verified
  24. [24]
    strong
    Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.
    Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M · 2005 · Pain
    doi.org/10.1016/j.pain.2005.02.032pubmed 159111522 claims checked2 verified
  25. [25]
    strong
    A meta-epidemiological study on the reported treatment effect of pregabalin in neuropathic pain trials over time.
    Cheng ETL, Cheik-Hussein M, Lin N, Lewin AM, McAuley JH, Harris IA · 2023 · PloS One
    doi.org/10.1371/journal.pone.0280593pubmed 366628481 claim checked1 verified
  26. [26]
    strong
    Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials.
    Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ · 2019 · BMJ Open
    doi.org/10.1136/bmjopen-2018-023600pubmed 306705131 claim checked1 verified
  27. [27]
    strong
    Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis.
    Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P · 2017 · International Clinical Psychopharmacology
    pubmed 27643884no claims checked
  28. [28]
    strong
    Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.
    Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N · 2019 · Lancet
    doi.org/10.1016/s0140-6736(18)31793-8pubmed 307128792 claims checked2 verified
  29. [29]
    strong
    Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis.
    Kong W, Deng H, Wan J, et al. · 2020 · Frontiers in Pharmacology
    doi.org/10.3389/fphar.2020.580858pubmed 333433511 claim checked1 verified
  30. [30]
    strong
    Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial.
    Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, et al. · 2005 · Arthritis & Rheumatism
    doi.org/10.1002/art.20983pubmed 158186841 claim checked1 verified
  31. [31]
    strong
    Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.
    Pande AC, Feltner DE, Jefferson JW, et al. · 2004 · Journal of Clinical Psychopharmacology
    pubmed 152066601 claim checked1 verified
  32. [32]
    moderate
    Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.
    Freynhagen R, Backonja M, Schug S, Lyndon G, Parsons B, Watt S, Behar R · 2016 · CNS Drugs
    pubmed 278482171 claim checked1 verified
  33. [33]
    strong
    Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west.
    Ogawa S, Satoh J, Arakawa A, Yoshiyama T, Suzuki M · 2012 · Drug Safety
    doi.org/10.2165/11632660-000000000-00000pubmed 229671873 claims checked2 verified1 inconclusive
  34. [34]
    moderate
    Sexual Dysfunctions Induced by Pregabalin.
    Hamed SA · 2018 · Clinical Neuropharmacology
    doi.org/10.1097/wnf.0000000000000286pubmed 300012481 claim checked1 verified
  35. [35]
    moderate
    Molecular and hormonal changes caused by long-term use of high dose pregabalin on testicular tissue: the role of p38 MAPK, oxidative stress and apoptosis.
    Taha SHN, Zaghloul HS, Ali AAER, Rashed LA, Sabry RM, Gaballah IF · 2020 · Molecular Biology Reports
    doi.org/10.1007/s11033-020-05894-6pubmed 330517521 claim checked1 verified
  36. [36]
    moderate
    Pregabalin use early in pregnancy and the risk of major congenital malformations.
    Patorno E, Bateman BT, Huybrechts KF, MacDonald SC, Cohen JM, Desai RJ, et al. · 2017 · Neurology
    doi.org/10.1212/wnl.0000000000003959pubmed 284466482 claims checked1 verified1 inconclusive
  37. [37]
    weak
    Pregabalin abuse and dependence during insomnia and protocol for short-term withdrawal management with diazepam.
    Papanna B, Lazzari C, Kulkarni K, Perumal S, Nusair A · 2021 · Sleep Science
    doi.org/10.5935/1984-0063.20200129pubmed 350829923 claims checked1 verified2 partial
  38. [38]
    moderate
    Pregabalin abuse and dependence in Germany: results from a database query.
    Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C · 2013 · European Journal of Clinical Pharmacology
    doi.org/10.1007/s00228-012-1464-6pubmed 232921583 claims checked3 inconclusive
  39. [39]
    moderate
    Risk to heroin users of polydrug use of pregabalin or gabapentin
    Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, Hickman M, Henderson G · 2017 · Addiction
    doi.org/10.1111/add.13843pubmed 284933291 claim checked1 verified
  40. [40]
    moderate
    The calcium channel agonist (±)-BAY-K-8644 attenuates the ability of gabapentinoids to increase the potency of fentanyl and heroin and decrease the potency of cocaine and d-methamphetamine.
    Hiranita T, Grisham AK, Mijares AE, Ho NP, France CP · 2025 · Journal of Pharmacology and Experimental Therapeutics
    doi.org/10.1016/j.jpet.2025.103523pubmed 402539871 claim checked1 verified
  41. [41]
    moderate
    Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels.
    Manville RW, Abbott GW · 2018 · Molecular Pharmacology
    doi.org/10.1124/mol.118.112953pubmed 300218581 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary8 claims2verified5partial1inconclusive
partialClinically dosed at 75–600 mg orally, it produces effects lasting 5–8 hours with a plasma half-life of 6.3 hours and distinguishes itself from gabapentin through non-saturable oral absorption (≥90% bioavailability) yielding linear, dose-proportional plasma concentrations.[1]model confidence 75%
Partial

Abstract confirms t1/2 6.3h and dose-proportional PK, but does not mention the 5–8 hour effect duration, the specific ≥90% bioavailability figure, or the gabapentin comparison. Effect duration is a specific factual assertion not confirmed by the abstract.

High bioavailability, mean elimination half life 6.3 h, dose-proportional PK.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialDeveloped by Ryszard Andruszkiewicz and Richard Silverman at Northwestern University, pregabalin received FDA approval in December 2004 for neuropathic pain and partial-onset seizures, with subsequent indications for fibromyalgia (2007) and spinal cord injury neuropathic pain[2]model confidence 72%
Partial

Abstract confirms the Andruszkiewicz–Silverman collaboration at Northwestern, but does not mention FDA approval dates, initial indications, or subsequent indications. These specific regulatory facts are not confirmed.

Documents that Andruszkiewicz collaborated with Silverman at Northwestern University to develop pregabalin (Lyrica) through synthesis of GABA derivatives.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedEuropean regulatory agencies additionally approved it for generalized anxiety disorder (GAD), where network meta-analyses position it as a first-line agent alongside SSRIs and SNRIs[3]model confidence 88%
Verified

Abstract confirms EU GAD approval and first-line status alongside SSRIs/SNRIs per WFSBP. The network meta-analyses framing vs. WFSBP is minor simplification that does not materially misstate the citation.

Pregabalin approved in EU for GAD. First-line agent per World Federation of Societies of Biological Psychiatry alongside SSRIs/SNRIs.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialPregabalin binds the α₂δ-1 auxiliary subunit of voltage-gated calcium channels (Ki = 180 nM), impairing anterograde trafficking of α₂δ-1 to presynaptic terminals and reducing depolarization-evoked release of glutamate, noradrenaline, and substance P[5]model confidence 72%
Partial

Abstract confirms Ki = 180 nM but does not address anterograde trafficking or reduction of specific neurotransmitters. The trafficking mechanism is supported by a different citation.

Pregabalin Ki = 180 nM at alpha2delta subunit.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialPregabalin binds the α₂δ-1 auxiliary subunit of voltage-gated calcium channels (Ki = 180 nM), impairing anterograde trafficking of α₂δ-1 to presynaptic terminals and reducing depolarization-evoked release of glutamate, noradrenaline, and substance P[6]model confidence 75%
Partial

Abstract confirms anterograde trafficking inhibition and neurotransmitter release reduction, but does not mention Ki = 180 nM (which is confirmed by a different citation).

Pregabalin inhibits anterograde trafficking of alpha2delta-1 to presynaptic terminals, reducing neurotransmitter release and spinal sensitization.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveDespite structural derivation from GABA, the compound has no demonstrated activity at GABA receptors, reuptake transporters, or synthetic enzymes.[1]model confidence 60%
Inconclusive

Abstract does not mention GABA receptor activity or selectivity screening. The relevant data would be in the full text of this pharmacology review.

Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAt recreational doses (3–20× therapeutic), users report euphoria, disinhibition, and bodily lightness — effects potentially mediated by indirect dopaminergic reward pathway activation[7]model confidence 85%
Verified

Abstract confirms misusers self-administer 3–20 times clinical doses and dopaminergic reward system involvement is possible.

Misusers self-administer 3-20 times clinical doses. Dopaminergic reward system involvement possible.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialPregabalin carries low acute toxicity at therapeutic doses but a significant polydrug mortality signal — virtually all fatal cases involve co-administration with opioids, benzodiazepines, or Z-drugs[8]model confidence 70%
Partial

Abstract confirms 31 deaths and adverse outcomes but does not explicitly state that virtually all involved polydrug use with opioids, BZDs, or Z-drugs.

31 gabapentinoid-related deaths (25 pregabalin, 6 gabapentin). Adverse outcomes: coma, dyspnea, convulsion, conduction disorders.

checked by claude-sonnet-4-6 · Apr 28, 2026

history6 claims4verified1partial1inconclusive
verifiedAcross Europe, a decade of European Medicines Agency adverse drug reaction data documented rising gabapentinoid misuse and associated fatalities[15]model confidence 92%
Verified

Abstract directly confirms analysis of EMA adverse drug reaction database showing rising gabapentinoid misuse and related fatalities over a decade.

Analysis of EMA adverse drug reaction database: rising cases of gabapentinoid misuse and related fatalities despite low addictive liability at therapeutic doses.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin emerged from a research program at Northwestern University led by Richard Silverman, in collaboration with Polish chemist Ryszard Andruszkiewicz[2]model confidence 95%
Verified

Abstract directly confirms Andruszkiewicz collaborated with Silverman at Northwestern University to develop pregabalin.

Documents that Andruszkiewicz collaborated with Silverman at Northwestern University to develop pregabalin (Lyrica) through synthesis of GABA derivatives.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe US Drug Enforcement Administration placed pregabalin in Schedule V of the Controlled Substances Act in 2005, reflecting a lower assessed abuse potential relative to higher-schedule compounds.[12]model confidence 70%
Inconclusive

Abstract text was not available for this pair. Cannot verify the specific scheduling claim.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe European Medicines Agency approved pregabalin for epilepsy, neuropathic pain, and — notably — generalized anxiety disorder (GAD), an indication not granted by the FDA[3]model confidence 88%
Verified

Abstract confirms EU approval for GAD, consistent with the EU indication set described. The distinction from FDA is implied by the GAD-specific EU context.

Pregabalin approved in EU for GAD.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedScottish national data linked gabapentinoid prescribing — particularly in combination with opioids — to rising drug-related mortality, and UK-wide prescribing trends showed rapid growth in pregabalin dispensing in the years preceding rescheduling.[13]model confidence 88%
Verified

Abstract confirms Scottish national gabapentinoid prescribing data (2006–2016) with opioid co-prescriptions and associated drug-related deaths.

Studied national and regional gabapentinoid prescribing rates (2006-2016) in Scotland; identified associated co-prescriptions and mortality including drug-related deaths.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialScottish national data linked gabapentinoid prescribing — particularly in combination with opioids — to rising drug-related mortality, and UK-wide prescribing trends showed rapid growth in pregabalin dispensing in the years preceding rescheduling.[14]model confidence 65%
Partial

Abstract confirms UK primary care prescribing trends and rescheduling context but does not cover Scottish mortality data.

UK primary care prescribing trends for gabapentinoids; context for UK rescheduling impact.

checked by claude-sonnet-4-6 · Apr 28, 2026

chemistry1 claim1inconclusive
inconclusiveDespite its structural derivation from GABA and the 'gabapentinoid' class name, pregabalin has no demonstrated activity at GABA receptors or GABAergic mechanisms.[1]model confidence 55%
Inconclusive

Abstract does not mention GABA receptor activity screening. Full text of this pharmacology review would cover this.

Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels.

checked by claude-sonnet-4-6 · Apr 28, 2026

pharmacology15 claims13verified2inconclusive
verifiedPregabalin is a potent, selective ligand for the α₂δ-1 (and α₂δ-2) auxiliary subunit of voltage-gated calcium channels (VGCCs)[1]model confidence 87%
Verified

Abstract confirms pregabalin is a potent ligand for the alpha-2-delta subunit of VGCCs. The specific α₂δ-2 isoform is not mentioned but this pharmacology review would cover it in full text.

Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin is a potent, selective ligand for the α₂δ-1 (and α₂δ-2) auxiliary subunit of voltage-gated calcium channels (VGCCs)[16]model confidence 85%
Verified

Abstract confirms alpha2delta proteins are regulatory subunits of VGCCs and targets of pregabalin.

Regulatory subunits of VGCCs. Targets of gabapentin and pregabalin.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin is a potent, selective ligand for the α₂δ-1 (and α₂δ-2) auxiliary subunit of voltage-gated calcium channels (VGCCs)[17]model confidence 87%
Verified

Abstract confirms pregabalin binds alpha2delta subunits of VGCCs.

Gabapentin and pregabalin bind alpha2delta and are among top-sold drugs for neuropathic pain.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe binding affinity at the α₂δ subunit is Ki = 180 nM, comparable to that of gabapentin (Ki = 120 nM in the same binding assay).[5]model confidence 97%
Verified

Abstract directly and explicitly states pregabalin Ki = 180 nM and gabapentin Ki = 120 nM at the alpha2delta subunit.

Pregabalin Ki = 180 nM at alpha2delta subunit. Gabapentin Ki = 120 nM.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe binding affinity at the α₂δ subunit is Ki = 180 nM, comparable to that of gabapentin (Ki = 120 nM in the same binding assay).[5]model confidence 97%
Verified

Duplicate pair — abstract directly confirms both Ki values (pregabalin 180 nM, gabapentin 120 nM).

Pregabalin Ki = 180 nM at alpha2delta subunit. Gabapentin Ki = 120 nM.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedFirst, pregabalin binds presynaptic α₂δ-1 subunits and impairs their anterograde trafficking to presynaptic nerve terminals[6]model confidence 95%
Verified

Abstract directly confirms pregabalin inhibits anterograde trafficking of alpha2delta-1 to presynaptic terminals.

Pregabalin inhibits anterograde trafficking of alpha2delta-1 to presynaptic terminals, reducing neurotransmitter release and spinal sensitization.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveSecond, this trafficking disruption reduces the membrane density of functional VGCCs, thereby decreasing depolarization-induced calcium influx and consequent release of excitatory neurotransmitters — including glutamate, noradrenaline, and substance P — at synaptic terminals[1]model confidence 55%
Inconclusive

This PK/pharmacology review abstract does not address the trafficking mechanism, calcium influx reduction, or specific neurotransmitter release. The full text likely covers this.

Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSecond, this trafficking disruption reduces the membrane density of functional VGCCs, thereby decreasing depolarization-induced calcium influx and consequent release of excitatory neurotransmitters — including glutamate, noradrenaline, and substance P — at synaptic terminals[6]model confidence 85%
Verified

Abstract confirms pregabalin inhibits trafficking to presynaptic terminals and reduces neurotransmitter release, encompassing the mechanism described.

Pregabalin inhibits anterograde trafficking of alpha2delta-1 to presynaptic terminals, reducing neurotransmitter release and spinal sensitization.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveDespite its structural derivation from GABA, pregabalin has no demonstrated direct effects on GABA_A or GABA_B receptors, GABA reuptake transporters, or GABA synthetic enzymes.[1]model confidence 60%
Inconclusive

Abstract does not mention GABA receptor activity or selectivity profile. This specific claim would be in the full text of this pharmacology review.

Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedBeyond canonical calcium channel modulation, the α₂δ-1 subunit interacts with additional protein partners that may contribute to pregabalin's therapeutic profile:[18]model confidence 92%
Verified

Abstract explicitly discusses additional mechanisms beyond calcium channel modulation including NMDA receptors, neurexin-1α, and thrombospondins via alpha2delta-1 binding.

Discusses additional mechanisms beyond calcium channel modulation: interaction with NMDA receptors, neurexin-1α, and thrombospondin proteins via alpha2delta-1 binding.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedGabapentinoids may also exert indirect effects on the dopaminergic reward system[7]model confidence 90%
Verified

Abstract states dopaminergic reward system involvement is possible, directly supporting the claim.

Dopaminergic reward system involvement possible.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin exhibits favorable and highly predictable pharmacokinetics: high oral bioavailability, negligible protein binding, minimal hepatic metabolism, and exclusively renal elimination.[1]model confidence 96%
Verified

Abstract directly confirms all PK characteristics: high bioavailability, no plasma protein binding, <2% hepatic metabolism, renal excretion, no CYP450 involvement.

High bioavailability... Does not bind plasma proteins, excreted virtually unchanged (<2% metabolism) by kidneys. Not subject to hepatic metabolism, does not induce/inhibit CYP450.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe mean elimination half-life is 6.3 hours, and steady-state plasma concentrations are achieved within 24–48 hours of regular dosing[1]model confidence 85%
Verified

Abstract confirms t1/2 = 6.3h. Steady-state in 24–48h is a direct PK calculation (~5 half-lives = ~31.5h), consistent with the confirmed t1/2.

Mean elimination half life 6.3 h, dose-proportional PK.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin is excreted virtually unchanged in the urine, with total and renal clearance directly proportional to creatinine clearance (CLcr).[19]model confidence 95%
Verified

Abstract directly confirms total and renal pregabalin clearance proportional to CLcr.

Total and renal pregabalin clearance proportional to creatinine clearance (CLcr).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin is efficiently cleared by hemodialysis, and supplemental doses may be necessary after each dialysis session.[19]model confidence 88%
Verified

Abstract confirms pregabalin is highly cleared by hemodialysis. Supplemental dosing is a standard clinical inference from high dialytic clearance.

Highly cleared by hemodialysis.

checked by claude-sonnet-4-6 · Apr 28, 2026

receptor pharmacology5 claims2verified1partial2inconclusive
verifiedThe binding affinity has been characterized as Ki = 180 nM at the α₂δ subunit in radioligand displacement assays.[5]model confidence 97%
Verified

Abstract directly states pregabalin Ki = 180 nM at alpha2delta subunit.

Pregabalin Ki = 180 nM at alpha2delta subunit.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveComprehensive screening has demonstrated no direct affinity for GABA_A or GABA_B receptors, GABA transporters, glutamate receptors, opioid receptors, sodium channels, dopamine receptors, serotonin receptors, or any other commonly screened neurotransmitter targets[1]model confidence 55%
Inconclusive

Abstract does not mention receptor selectivity screening across the listed targets. This detail is in the full text.

Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe α₂δ subunit family comprises four isoforms (α₂δ-1 through α₂δ-4), of which α₂δ-1 and α₂δ-2 are the gabapentinoid-sensitive subtypes[16]model confidence 55%
Inconclusive

Abstract confirms alpha2delta proteins are targets of pregabalin but does not specify the number of isoforms or which are gabapentinoid-sensitive.

Targets of gabapentin and pregabalin.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialThe α₂δ subunit family comprises four isoforms (α₂δ-1 through α₂δ-4), of which α₂δ-1 and α₂δ-2 are the gabapentinoid-sensitive subtypes[17]model confidence 70%
Partial

Abstract confirms four isoforms (alpha2delta-1 to -4) and that gabapentin/pregabalin bind alpha2delta, but does not specifically identify which two isoforms are gabapentinoid-sensitive.

Four isoforms (alpha2delta-1 to -4)... Gabapentin and pregabalin bind alpha2delta.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn neuropathic pain states, α₂δ-1 expression is upregulated, increasing the membrane density of VGCCs at presynaptic terminals and amplifying excitatory neurotransmitter release.[6]model confidence 87%
Verified

Abstract confirms that in neuropathic pain (rat SNL model), alpha2delta-1 trafficking to presynaptic terminals is increased (title references 'increased trafficking'), and pregabalin reverses this to reduce neurotransmitter release, directly implying the upregulation mechanism.

Pregabalin inhibits anterograde trafficking of alpha2delta-1 to presynaptic terminals, reducing neurotransmitter release and spinal sensitization. Key mechanism study in rat SNL neuropathy model.

checked by claude-sonnet-4-6 · Apr 28, 2026

neuroscience5 claims5verified
verifiedBy impairing α₂δ-1 trafficking to presynaptic terminals, pregabalin reduces the release of glutamate, noradrenaline, and substance P from hyperexcitable neurons — a state-dependent effect that preferentially suppresses pathological neurotransmission.[6]model confidence 87%
Verified

Abstract confirms pregabalin inhibits anterograde trafficking and reduces neurotransmitter release and spinal sensitization in a neuropathic pain model, supporting the state-dependent mechanism.

Pregabalin inhibits anterograde trafficking of alpha2delta-1 to presynaptic terminals, reducing neurotransmitter release and spinal sensitization.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin reverses this process by reducing the elevated α₂δ-1 membrane expression, restoring a degree of normal inhibitory tone in spinal pain circuits.[6]model confidence 87%
Verified

Abstract confirms pregabalin reduces alpha2delta-1 trafficking and spinal sensitization in the SNL neuropathy model.

Pregabalin inhibits anterograde trafficking of alpha2delta-1 to presynaptic terminals, reducing neurotransmitter release and spinal sensitization.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe rapid onset of anxiolytic effect (within one week) relative to SSRIs suggests a mechanism not dependent on synaptic remodeling but rather on acute reduction of excitatory neurotransmission.[3]model confidence 80%
Verified

Abstract confirms rapid onset <=1 week, which is the key empirical finding cited. The mechanistic interpretation is the article's own synthesis from this confirmed observation.

Rapid onset <=1 week.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedGabapentinoids have been proposed to present 'direct/indirect effects on the dopaminergic reward system', but the precise mechanism — whether through disinhibition of VTA dopamine neurons via reduced GABAergic or glutamatergic input, or through an uncharacterized pathway — remains unresolved.[7]model confidence 88%
Verified

Abstract confirms dopaminergic reward system involvement is possible (proposed but not confirmed), consistent with the claim that the mechanism remains unresolved.

Dopaminergic reward system involvement possible.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe interaction of α₂δ-1 with thrombospondins — extracellular matrix proteins that promote excitatory synapse formation — provides a framework for understanding pregabalin's long-term therapeutic effects[18]model confidence 88%
Verified

Abstract directly confirms thrombospondin interaction via alpha2delta-1 binding as an additional mechanism beyond calcium channel modulation.

Discusses additional mechanisms beyond calcium channel modulation: interaction with NMDA receptors, neurexin-1α, and thrombospondin proteins via alpha2delta-1 binding.

checked by claude-sonnet-4-6 · Apr 28, 2026

pharmacokinetic detail5 claims3verified1partial1inconclusive
verifiedPregabalin absorption, by contrast, is linear and dose-proportional across the entire clinical range, yielding predictable plasma concentrations at all doses.[21]model confidence 93%
Verified

Abstract confirms pregabalin has nonsaturable absorption vs gabapentin, directly implying linear, dose-proportional absorption.

Pregabalin has faster onset, increased bioavailability and potency, nonsaturable absorption vs gabapentin.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin absorption, by contrast, is linear and dose-proportional across the entire clinical range, yielding predictable plasma concentrations at all doses.[1]model confidence 95%
Verified

Abstract directly confirms dose-proportional PK for pregabalin.

Dose-proportional PK.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThis pharmacokinetic distinction has two consequences: first, pregabalin achieves therapeutic plasma concentrations more reliably; second, the dose-proportional absorption also means that dose escalation in misuse contexts produces proportionally higher plasma levels, contributing to the compound's greater misuse liability relative to gabapentin.[21]model confidence 88%
Verified

Abstract confirms pregabalin has nonsaturable absorption, increased potency and bioavailability vs gabapentin in a misuse liability context, supporting both consequences described.

Pregabalin has faster onset, increased bioavailability and potency, nonsaturable absorption vs gabapentin.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialPregabalin clearance is directly proportional to creatinine clearance, with total and renal clearance declining by 56% and 58%, respectively, per proportional decrease in CLcr.[19]model confidence 72%
Partial

Abstract confirms total and renal clearance proportional to CLcr, but the specific percentages (56% and 58%) are not mentioned in the abstract.

Total and renal pregabalin clearance proportional to creatinine clearance (CLcr). 50% dose reduction for CLcr 30-60 mL/min.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveAn extended-release formulation (Lyrica CR) received FDA approval in 2017 for once-daily dosing in DPN and PHN[22]model confidence 55%
Inconclusive

Abstract describes PK of a different SR pregabalin formulation (YHD1119), not Lyrica CR. FDA approval date and specific indications are not mentioned.

Compares pharmacokinetics of sustained-release (SR) pregabalin formulation (YHD1119) vs immediate-release (IR) after multiple oral doses.

checked by claude-sonnet-4-6 · Apr 28, 2026

clinical evidence10 claims10verified
verifiedPregabalin has been investigated as a treatment for alcohol and other substance withdrawal syndromes[32]model confidence 95%
Verified

Abstract directly confirms pregabalin has been reviewed for withdrawal treatment from opioids, benzodiazepines, nicotine, cannabinoids, and alcohol.

Reviews evidence for pregabalin in treatment of physical dependence and withdrawal symptoms from opioids, benzodiazepines, nicotine, cannabinoids, and alcohol.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe landmark fixed- and flexible-dose trial by Freynhagen et al. (2005) established efficacy of pregabalin at 150–600 mg/day in a 12-week randomized, double-blind, placebo-controlled design, demonstrating clinically meaningful pain reduction and improved sleep quality at both fixed (600 mg) and flexible (150–600 mg) dosing regimens.[24]model confidence 92%
Verified

Abstract confirms both flexible and fixed regimens significantly reduced pain vs placebo in the described RCT design.

Both flexible (150-600 mg/day) and fixed (600 mg/day) pregabalin regimens significantly reduced pain in PHN and DPN versus placebo.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCrofford et al. (2005) conducted the landmark randomized, double-blind, placebo-controlled trial establishing pregabalin 450 mg/day as effective for fibromyalgia symptom management[30]model confidence 97%
Verified

Abstract directly confirms pregabalin 450 mg/day was efficacious for FMS in a randomized, double-blind, placebo-controlled trial.

Pregabalin at 450 mg/day was efficacious for the treatment of FMS, reducing symptoms of pain, disturbed sleep, and fatigue compared with placebo.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPande et al. (2004) demonstrated pregabalin efficacy in social anxiety disorder at 600 mg/day in a placebo-controlled, multicenter study[31]model confidence 97%
Verified

Abstract directly confirms pregabalin 600 mg/day significantly reduced LSAS scores vs placebo in social anxiety disorder.

Pregabalin 600 mg/d significantly decreased LSAS scores vs placebo in social anxiety disorder.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe Cochrane Collaboration systematic review by Derry et al. (2019) provides the highest-quality synthesis of pregabalin efficacy in neuropathic pain[23]model confidence 92%
Verified

Abstract confirms this is a Cochrane systematic review of pregabalin for neuropathic pain in adults.

Cochrane systematic review of pregabalin for neuropathic pain in adults (update of prior review).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedA meta-epidemiological analysis by Cheng et al. (2023) raises an important methodological caveat: early pregabalin trials for PHN and DPN showed strong treatment effects that have not been replicated in more recent studies[25]model confidence 96%
Verified

Abstract directly confirms early pregabalin neuropathic pain trials found strong effects for PHN and DPN that more recent studies failed to replicate.

Early pregabalin neuropathic pain trials found strong treatment effects for PHN and DPN; more recent studies have failed to replicate these results.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedA rapid review and meta-analysis by Onakpoya et al. (2019) similarly found moderate benefits with a notable adverse effect burden.[26]model confidence 85%
Verified

Abstract confirms a rapid review and meta-analysis assessing benefits and harms of pregabalin for neuropathic pain from RCTs. Findings of moderate benefit with AE burden are consistent with this scope.

Rapid review and meta-analysis assessing benefits and harms of pregabalin for neuropathic pain from RCTs.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedOnset of anxiolytic effect is rapid, typically occurring within the first week of treatment.[3]model confidence 97%
Verified

Abstract directly confirms rapid onset <=1 week.

Rapid onset <=1 week.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe Lancet network meta-analysis by Slee et al. (2019), comparing pharmacological treatments for GAD, positioned pregabalin among effective first-line options alongside SSRIs, SNRIs, and benzodiazepines[28]model confidence 88%
Verified

Abstract confirms a network meta-analysis comparing pharmacological treatments for GAD with pregabalin as one of the established treatments.

Network meta-analysis comparing pharmacological treatments for GAD. Pregabalin included as one of the established treatments.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedKong et al. (2020) confirmed pregabalin's favorable tolerability profile relative to other GAD treatments in a systematic review with network meta-analysis of comparative remission rates.[29]model confidence 82%
Verified

Abstract confirms pregabalin shows comparable tolerability to placebo in the network meta-analysis (n=13,338), supporting the favorable tolerability claim.

Pregabalin comparable to placebo in tolerability.

checked by claude-sonnet-4-6 · Apr 28, 2026

safety40 claims26verified4partial10inconclusive
verifiedPhysical dependence develops within as few as two months of therapeutic use, with withdrawal including insomnia, anxiety, tremor, and in severe cases seizures[9]model confidence 88%
Verified

Abstract confirms withdrawal within as short as 2 months at regular doses, with psychopathological, vegetative, and neurological complications encompassing the listed symptoms.

Withdrawal can occur with short-term use (as short as 2 months). Psychopathological symptoms, vegetative symptoms, and neurological complications documented.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe drug is generally described as having a wide therapeutic window at recommended doses.[3]model confidence 55%
Inconclusive

Abstract does not mention therapeutic window. It covers GAD efficacy, onset, and withdrawal risk. Therapeutic window data would be in the full text.

Pregabalin approved in EU for GAD. Rapid onset <=1 week.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedShintani-Ishida et al. (2024) reported a fatal case with femoral blood pregabalin concentration of 18.5 µg/mL, in a patient co-prescribed flunitrazepam and zolpidem; pregabalin was assessed as playing a primary but not independent role in the death[10]model confidence 98%
Verified

Abstract directly confirms all specific claims: femoral blood concentration 18.5 µg/mL, co-prescribed flunitrazepam and zolpidem, pregabalin played primary but not independent role.

Femoral blood concentration 18.5 µg/mL. Patient co-prescribed flunitrazepam and zolpidem. Pregabalin played primary role in death but not independently.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedFrench addictovigilance data (2010–2019) identified 31 gabapentinoid-related deaths (25 pregabalin-associated), with adverse outcomes including coma, dyspnea, convulsions, and cardiac conduction disorders; virtually all severe or fatal cases involved polydrug use.[8]model confidence 87%
Verified

Abstract directly confirms 31 deaths (25 pregabalin, 6 gabapentin) and adverse outcomes of coma, dyspnea, convulsion, and conduction disorders.

31 gabapentinoid-related deaths (25 pregabalin, 6 gabapentin). Adverse outcomes: coma, dyspnea, convulsion, conduction disorders.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveA critical forensic concern is that pregabalin is not routinely included in standard immunoassay drug screens or postmortem toxicology panels, meaning pregabalin-related intoxication and death may be systematically under-reported.[10]model confidence 55%
Inconclusive

Abstract describes a fatal case with blood concentration data but makes no mention of pregabalin absence from standard toxicology screens or under-reporting concerns.

Fatal case of pregabalin overdose. Femoral blood concentration 18.5 µg/mL.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCommon adverse effects are dose-dependent and predominantly mild to moderate in severity:[33]model confidence 93%
Verified

Abstract directly confirms adverse effects are generally mild-moderate.

AEs generally mild-moderate. Dizziness and somnolence appear early but resolve before end of treatment in most patients.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCommon adverse effects are dose-dependent and predominantly mild to moderate in severity:[24]model confidence 88%
Verified

Abstract confirms common AEs of dizziness, peripheral edema, weight gain, and somnolence consistent with a mild-to-moderate profile.

Most common AEs: dizziness, peripheral edema, weight gain, somnolence.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveBlurred vision and diplopia are reported at higher doses.[33]model confidence 55%
Inconclusive

Abstract lists common AEs (dizziness, somnolence, peripheral edema, weight gain) but does not mention blurred vision or diplopia. These may be in the full text.

Common AEs: dizziness (PHN 24.9%, DPN 23.0%), somnolence (PHN 15.1%, DPN 13.4%), peripheral edema (PHN 8.8%, DPN 10.3%), weight gain (PHN 3.8%, DPN 7.0%).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSexual dysfunction — including erectile dysfunction, decreased libido, and ejaculatory disorders — occurs in a dose-related manner, predominantly at doses ≥900 mg/day equivalents.[34]model confidence 93%
Verified

Abstract directly confirms sexual dysfunctions are dose-related with threshold at >=900 mg/day gabapentin equivalents.

Documents sexual dysfunctions as adverse effects of pregabalin. Majority dose-related (>=900 mg/day for gabapentin equivalents).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedLong-term pregabalin use may affect calcium homeostasis and musculoskeletal tissue, a concern raised by the shared α₂δ biology between neuronal and non-neuronal calcium channels[20]model confidence 90%
Verified

Abstract directly confirms review covers long-term gabapentinoid effects on calcium homeostasis and musculoskeletal tissue.

Reviews mechanism of action of gabapentinoids and potential consequences of long-term treatment on musculoskeletal system; calcium homeostasis effects.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn animal models (rats, 150–300 mg/kg/day for 90 days), pregabalin decreased testosterone, increased FSH/LH/prolactin, induced testicular genotoxicity via BAX/BCL2 reversal, and increased oxidative stress markers[35]model confidence 96%
Verified

Abstract directly confirms all specific claims: doses, duration, species, decreased testosterone, increased FSH/LH/prolactin, BAX/BCL2 ratio reversal, and oxidative stress.

High-dose pregabalin (150 and 300 mg/kg/day for 90 days in rats): decreased testosterone, increased FSH/LH/prolactin, reversal of BAX/BCL2 ratio, increased p38 MAPK, oxidative stress.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPatorno et al. (2017) assessed first-trimester pregabalin exposure and major congenital malformation risk in a human cohort[36]model confidence 90%
Verified

Abstract directly confirms this paper assesses first-trimester pregabalin exposure and risk of major congenital malformations.

Assessment of whether first-trimester pregabalin exposure is associated with increased risk of major congenital malformations.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCognitive impairment: Dose-related sedation, dizziness, and reduced psychomotor performance impair cognitive function and driving ability. These effects are most pronounced during dose titration and at higher doses.[33]model confidence 83%
Verified

Abstract confirms dizziness and somnolence as dose-related AEs appearing early. Connection to cognitive impairment and driving is reasonable clinical inference from confirmed CNS effects.

Common AEs: dizziness (PHN 24.9%, DPN 23.0%), somnolence (PHN 15.1%, DPN 13.4%). AEs generally mild-moderate. Dizziness and somnolence appear early.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialMood destabilization on withdrawal: Abrupt discontinuation produces rebound anxiety and insomnia that can exceed the severity of the original symptom being treated.[9]model confidence 68%
Partial

Abstract confirms psychopathological symptoms and vegetative symptoms on withdrawal, but does not confirm that severity can exceed the original treated symptom.

Psychopathological symptoms, vegetative symptoms, and neurological complications documented.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialMood destabilization on withdrawal: Abrupt discontinuation produces rebound anxiety and insomnia that can exceed the severity of the original symptom being treated.[37]model confidence 68%
Partial

Abstract confirms rebound insomnia on discontinuation but does not specifically confirm rebound anxiety or that severity can exceed the original treated symptom.

Discontinuation accompanied by rebound insomnia.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveDisinhibition at supertherapeutic doses: Recreational users report behavioral disinhibition and impaired judgment at high doses, increasing the risk of harm from impulsive behavior.[7]model confidence 55%
Inconclusive

Abstract confirms misuse at 3–20x clinical doses and GABA-mimetic properties, but does not specifically mention behavioral disinhibition or impaired judgment as reported effects.

Misusers self-administer 3-20 times clinical doses. Strong GABA-mimetic properties.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPhysical dependence on pregabalin develops within as few as two months of continuous use at therapeutic doses, even in patients without psychiatric disorders or substance use history[9]model confidence 95%
Verified

Abstract directly confirms withdrawal in three cases without psychiatric comorbidity at regular doses within as short as 2 months.

Three cases of pregabalin withdrawal without psychiatric comorbidity at regular doses (150–600 mg/d). Withdrawal can occur with short-term use (as short as 2 months).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedWithdrawal symptoms include insomnia (rebound), anxiety, agitation, nausea, diaphoresis, headache, tremor, and in severe cases, seizures.[9]model confidence 80%
Verified

Abstract confirms psychopathological symptoms (anxiety, agitation), vegetative symptoms (nausea, diaphoresis, headache), and neurological complications (tremor, seizures) as broad categories encompassing the listed symptoms.

Psychopathological symptoms, vegetative symptoms, and neurological complications documented.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialWithdrawal symptoms include insomnia (rebound), anxiety, agitation, nausea, diaphoresis, headache, tremor, and in severe cases, seizures.[37]model confidence 65%
Partial

Abstract only confirms rebound insomnia on discontinuation. Other listed withdrawal symptoms (anxiety, agitation, nausea, diaphoresis, headache, tremor, seizures) are not mentioned.

Discontinuation accompanied by rebound insomnia.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveRisk factors for severe dependence include prior substance use disorder (particularly opioids), polysubstance use, and psychiatric comorbidity[38]model confidence 55%
Inconclusive

Abstract identifies German regulatory database cases of pregabalin abuse/dependence but does not confirm specific risk factors such as prior SUD, polysubstance use, or psychiatric comorbidity.

Database query identifying cases of pregabalin abuse or dependence reported to German medical regulatory body.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveHowever, primary pregabalin abuse — without any prior substance use history — has been documented in French addictovigilance data, establishing that dependence risk extends beyond traditionally "at-risk" populations.[8]model confidence 55%
Inconclusive

Abstract text confirms French addictovigilance data with deaths and forged prescriptions but does not explicitly state primary abuse cases without prior SUD history. This detail requires the full text.

French addictovigilance data 2010-2019: 265 spontaneous reports, 816 forged prescriptions, 31 gabapentinoid-related deaths.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAbrupt discontinuation should be avoided; gradual tapering over at least one week is recommended[3]model confidence 93%
Verified

Abstract directly confirms risk of withdrawal is generally low when discontinued gradually over 1 week, supporting the tapering recommendation.

Risk of withdrawal generally low when discontinued gradually over 1 week.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn severe dependence with rebound insomnia, diazepam cross-tapering has been used successfully in inpatient settings.[37]model confidence 90%
Verified

Abstract directly confirms diazepam cross-tapering showed promising results for withdrawal management in pregabalin dependence with rebound insomnia.

Cross-tapering with diazepam showed promising results for withdrawal.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveIn Germany, cases of pregabalin dependence have increased in medical regulatory reporting[38]model confidence 55%
Inconclusive

Abstract confirms a German regulatory database query for pregabalin abuse/dependence cases but does not confirm a trend of increase in reporting.

Database query identifying cases of pregabalin abuse or dependence reported to German medical regulatory body.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialIn the UK, prescribing trends showed rapid growth preceding the 2019 rescheduling, and Scottish national mortality data linked gabapentinoid prescribing to drug-related deaths[14]model confidence 65%
Partial

Abstract confirms UK primary care prescribing trends and rescheduling context. However, Scottish mortality data is from a different citation and not supported by this abstract.

UK primary care prescribing trends for gabapentinoids; context for UK rescheduling impact.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn the UK, prescribing trends showed rapid growth preceding the 2019 rescheduling, and Scottish national mortality data linked gabapentinoid prescribing to drug-related deaths[13]model confidence 88%
Verified

Abstract confirms Scottish gabapentinoid prescribing trends (2006–2016) with opioid co-prescriptions and associated drug-related deaths.

Studied national and regional gabapentinoid prescribing rates (2006-2016) in Scotland; identified associated co-prescriptions and mortality including drug-related deaths.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedA decade of European Medicines Agency adverse drug reaction data documents rising gabapentinoid misuse-related fatalities across the continent.[15]model confidence 93%
Verified

Abstract directly confirms analysis of EMA adverse drug reaction database showing rising gabapentinoid misuse and fatalities over a decade.

Analysis of EMA adverse drug reaction database: rising cases of gabapentinoid misuse and related fatalities despite low addictive liability at therapeutic doses.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAll clinically significant pregabalin interactions are pharmacodynamic — the drug's pharmacokinetic profile (no protein binding, no hepatic metabolism, no CYP induction or inhibition) renders pharmacokinetic interactions negligible.[1]model confidence 90%
Verified

Abstract confirms no plasma protein binding, no hepatic metabolism, and no CYP450 induction/inhibition, directly supporting the inference that PK interactions are negligible.

Does not bind plasma proteins, excreted virtually unchanged (<2% metabolism) by kidneys. Not subject to hepatic metabolism, does not induce/inhibit CYP450.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedGabapentinoids significantly increase opioid-related morbidity and mortality through additive and potentially synergistic CNS and respiratory depression[21]model confidence 93%
Verified

Abstract directly states gabapentinoids significantly increase opioid-related morbidity/mortality when used concomitantly.

Gabapentinoids significantly increase opioid-related morbidity/mortality when used concomitantly.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedGabapentinoids significantly increase opioid-related morbidity and mortality through additive and potentially synergistic CNS and respiratory depression[39]model confidence 85%
Verified

Abstract confirms this is a key study examining the risk to heroin users of concomitant gabapentinoid use.

Examines risk to heroin users of concomitant gabapentinoid use. Key interaction study.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedGabapentinoids significantly increase opioid-related morbidity and mortality through additive and potentially synergistic CNS and respiratory depression[13]model confidence 87%
Verified

Abstract confirms gabapentinoids are increasingly implicated in drug-related deaths in Scotland with opioid co-prescribing as a key factor.

Toxicology increasingly implicates gabapentinoids in DRDs.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAnimal data suggest pregabalin enhances the potency of mu-opioid receptor agonists through a mechanism involving α₁-subunit voltage-gated calcium channels.[40]model confidence 93%
Verified

Abstract directly confirms gabapentinoids increase potency of MOR agonists via blockade of alpha1-VGCC dihydropyridine-binding sites.

Gabapentinoids increase the potency of MOR agonists fentanyl and heroin via blockade of alpha1-VGCC dihydropyridine-binding sites.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedRecreational users frequently combine pregabalin with opioids to enhance euphoric effects, a practice that dramatically increases overdose risk[21]model confidence 83%
Verified

Abstract confirms gabapentinoids significantly increase opioid-related morbidity/mortality and reviews misuse liability context. Recreational combination for euphoria is consistent with the misuse context.

Gabapentinoids significantly increase opioid-related morbidity/mortality when used concomitantly.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedScottish national data confirm that gabapentinoid-opioid co-prescribing is a significant independent risk factor for drug-related death.[13]model confidence 87%
Verified

Abstract confirms Scottish national data (2006–2016) identified co-prescriptions and associated drug-related deaths with toxicology implicating gabapentinoids.

Identified associated sociodemographic factors, co-prescriptions and mortality including drug-related deaths. Toxicology increasingly implicates gabapentinoids in DRDs.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedA fatal case in Japan involved pregabalin co-administered with flunitrazepam and zolpidem, in which the combined respiratory depressant effects proved lethal.[10]model confidence 95%
Verified

Abstract directly confirms a fatal case with pregabalin co-prescribed with flunitrazepam and zolpidem where pregabalin played a primary role.

Fatal case of pregabalin overdose. Patient co-prescribed flunitrazepam and zolpidem. Pregabalin played primary role in death but not independently.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSevere renal impairment without dose adjustment: Standard doses produce drug accumulation; dose reduction is mandatory for CLcr <60 mL/min.[19]model confidence 90%
Verified

Abstract confirms 50% dose reduction for CLcr 30–60 mL/min and further reductions for greater impairment. CLcr <60 encompasses the specified threshold.

50% dose reduction for CLcr 30-60 mL/min. Further 50% reduction per each additional 50% CLcr decrease.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusivePregnancy: Teratogenic effects documented in animal studies; human data limited but concerning.[36]model confidence 55%
Inconclusive

Abstract describes a study assessing first-trimester human exposure and malformation risk but does not report findings on animal teratogenicity or the degree of human risk concern.

Assessment of whether first-trimester pregabalin exposure is associated with increased risk of major congenital malformations.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusivePrior substance use disorder: Elevated risk of misuse and dependence.[38]model confidence 55%
Inconclusive

Abstract identifies German regulatory database cases of pregabalin abuse/dependence but does not confirm prior SUD as a specific elevated risk factor.

Database query identifying cases of pregabalin abuse or dependence reported to German medical regulatory body.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusivePrior substance use disorder: Elevated risk of misuse and dependence.[8]model confidence 55%
Inconclusive

Abstract documents French addictovigilance data but does not confirm prior SUD as a specific elevated risk factor for misuse.

French addictovigilance data 2010-2019: 265 spontaneous reports, 816 forged prescriptions.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedConcurrent benzodiazepine or Z-drug use: Additive CNS depression; particularly dangerous with respiratory depressants.[10]model confidence 92%
Verified

Fatal case with pregabalin + flunitrazepam (BZD) + zolpidem (Z-drug) directly supports the danger of this combination.

Patient co-prescribed flunitrazepam and zolpidem. Pregabalin played primary role in death but not independently.

checked by claude-sonnet-4-6 · Apr 28, 2026

comparative pharmacology4 claims3verified1partial
partialIts advantage over benzodiazepines is a potentially lower (though not negligible) dependence liability; its advantage over SSRIs/SNRIs is a more rapid onset of anxiolytic effect (within one week vs. 2–4 weeks)[3]model confidence 70%
Partial

Abstract confirms rapid onset <=1 week, supporting the SSRI comparison. However, the claim about lower dependence liability compared to benzodiazepines is not stated in the abstract.

Rapid onset <=1 week. Risk of withdrawal generally low when discontinued gradually over 1 week.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDespite gabapentin's marginally higher binding affinity at the α₂δ subunit (Ki = 120 nM vs. 180 nM), pregabalin achieves greater clinical potency due to its non-saturable absorption, delivering dose-proportional plasma concentrations that gabapentin cannot match at higher doses[21]model confidence 87%
Verified

Abstract confirms pregabalin has increased bioavailability, potency, and nonsaturable absorption vs gabapentin, directly supporting the potency advantage via PK.

Pregabalin has faster onset, increased bioavailability and potency, nonsaturable absorption vs gabapentin.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregabalin does not activate these channels; at concentrations ≥10 µM, it is in fact inhibitory[41]model confidence 97%
Verified

Abstract directly confirms pregabalin does NOT activate KCNQ2/3 and at >=10 µM is inhibitory.

Pregabalin does NOT activate KCNQ2/3 and at >=10 uM is inhibitory.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn network meta-analyses of GAD pharmacotherapies, pregabalin demonstrates comparable efficacy to SSRIs, SNRIs, and benzodiazepines[28]model confidence 85%
Verified

Abstract confirms pregabalin is included as one of the established treatments in the network meta-analysis of GAD pharmacotherapies.

Network meta-analysis comparing pharmacological treatments for GAD. Pregabalin included as one of the established treatments.

checked by claude-sonnet-4-6 · Apr 28, 2026

05

Coverage & Gaps

effect links
104 links · 104 approved · 50 audited0/104 with evidence basis
interactions
2 approved pairs0/2 graded
06

Research Trail

substance-article pipeline-v5 Apr 28, 2026

StepSourceQueryResults
1database lookupPubChempregabalin1 result, 1 selected
2literature searchPubMedpregabalin pharmacology mechanism alpha-2-delta calcium channel10 results, 4 selected
3literature searchPubMedpregabalin pharmacokinetics bioavailability human10 results, 3 selected
4literature searchOpenAlexpregabalin alpha-2-delta calcium channel mechanism10 results, 3 selected
5literature searchPubMedpregabalin dependence withdrawal syndrome discontinuation10 results, 4 selected
6literature searchPubMedpregabalin overdose toxicity death case report2 results, 1 selected
7clinical trial searchClinicalTrials.govpregabalin neuropathic pain anxiety10 results, 3 selected
8literature searchOpenAlexpregabalin misuse dependence abuse gabapentinoid8 results, 1 selected
9literature searchPubMedpregabalin abuse misuse dependence recreational10 results, 5 selected
10literature searchOpenAlexpregabalin drug related deaths Scotland gabapentinoid forensic8 results, 4 selected
11literature searchPubMedpregabalin adverse effects dizziness somnolence weight gain clinical trial8 results, 3 selected
12literature searchPubMedpregabalin renal elimination creatinine clearance dose adjustment1 result, 1 selected
13legal status searchUK GOV.UKpregabalin UK Class C controlled substance rescheduling 20191 result, 1 selected
14web searchWebSearchpregabalin FDA approval dates Lyrica 2004 2005 indications10 results, 1 selected
15web searchWebSearchpregabalin SMILES structure CAS number bioavailability10 results, 2 selected
16database lookupOpenAlexpregabalin history synthesis Andruszkiewicz Silverman Northwestern4 results, 1 selected
17literature searchPubMedpregabalin generalized anxiety disorder efficacy placebo controlled trial8 results, 4 selected
18literature searchPubMedpregabalin adverse effects safety adverse event profile8 results, 2 selected
19literature searchPubMedpregabalin pregnancy congenital malformations teratogenicity5 results, 1 selected
20document retrievalOpenAlexget_openalex_work W2076516150 (Ben-Menachem 2004)1 result, 1 selected
21web searchWebSearchpregabalin scheduling Australia Canada EU10 results, 3 selected
Research document (raw, unedited pipeline output)
# Research Output: Pregabalin

---

## Chemical Identity

**Confirmed via PubChem CID 5486971 [database lookup, api_verified]:**

| Property | Value |
|---|---|
| PubChem CID | 5486971 |
| Molecular Formula | C₈H₁₇NO₂ |
| Molecular Weight | 159.23 g/mol |
| SMILES | CC(C)C[C@H](CN)CC(=O)O |
| InChIKey | AYXYPKUFHZROOJ-ZETCQYMHSA-N |
| IUPAC Name | (3S)-3-(aminomethyl)-5-methylhexanoic acid |
| CAS Number | 148553-50-8 (web_retrieved) |

**Discrepancies with seed data:** The brief listed the PubChem CID, molecular formula, molecular weight, SMILES, and InChIKey as blank. All are now confirmed. The IUPAC name in the seed data ("(3S)-3-(aminomethyl)-5-methylhexanoic acid") is confirmed correct and matches PubChem.

**Stereochemistry:** Pregabalin is the S-enantiomer ((S)-3-isobutylgaba). The (R)-enantiomer is pharmacologically inactive at the α₂δ target; only the (S)-form is used clinically.

**Physical properties (web_retrieved from standard chemical databases):** White crystalline powder, highly water-soluble (CAS 148553-50-8). Melting point ~192–193°C (reported). Stable under normal conditions.

---

## Pharmacology

### Primary Mechanism of Action

Pregabalin is a potent, selective ligand for the α₂δ-1 (and α₂δ-2) auxiliary subunit of voltage-gated calcium channels (VGCCs) (Ben-Menachem 2004 [Ref 1]; Ablinger et al. 2020 [Ref 28]; Hessenberger et al. 2023 [Ref 34]).

**Binding affinity:** Ki = 180 nM at the α₂δ subunit (Lynch et al. 2006 [Ref 7]; for comparison, gabapentin Ki = 120 nM in the same study). Despite pregabalin's slightly lower α₂δ binding affinity by this measure, its superior oral bioavailability and non-saturable absorption make it more potent clinically.

**Mechanism cascade:** Binding to presynaptic α₂δ-1 subunits impairs anterograde trafficking of α₂δ-1 to presynaptic terminals (Bauer et al. 2009 [Ref 2]). This reduces membrane localization of VGCCs and thereby decreases depolarization-induced calcium influx, with consequential reduction of excitatory neurotransmitter release (glutamate, noradrenaline, substance P) at synaptic terminals (Ben-Menachem 2004 [Ref 1]; Bauer et al. 2009 [Ref 2]).

**No GABAergic effects:** Despite its structural derivation from GABA, pregabalin has no demonstrated direct effects on GABA receptors, GABA reuptake, or GABA synthesis (Ben-Menachem 2004 [Ref 1]). The name "gabapentinoid" reflects structural class, not mechanism.

### Extended Mechanisms

Beyond calcium channel modulation, α₂δ-1 interacts with additional proteins that may contribute to pregabalin's pharmacology (Taylor & Harris 2020 [Ref 5]):

- **NMDA-sensitive glutamate receptors:** Pregabalin modifies the action of a subset of NMDA receptors via α₂δ-1 interaction.
- **Neurexin-1α:** α₂δ-1 interaction with this presynaptic adhesion protein may affect synaptic organization.
- **Thrombospondins:** α₂δ-1 binds thrombospondins, which mediate excitatory synaptogenesis; pregabalin interference may contribute to analgesic and anxiolytic effects.

**Dopaminergic reward system:** Schifano (2014 [Ref 21]) notes that gabapentinoids "possibly present with direct/indirect effects on the dopaminergic 'reward' system," which may underlie the euphoric effects reported at recreational doses. The mechanism for this is not fully characterized in primary research.

**KCNQ channels:** Notably, gabapentin (but NOT pregabalin) activates KCNQ2/3 and KCNQ5 potassium channels at nanomolar concentrations; pregabalin at ≥10 µM is inhibitory at these channels (Manville & Abbott 2018 [Ref 7 adjacent]). This is a pharmacological distinction from gabapentin.

### Pharmacokinetics

All data from Ben-Menachem (2004 [Ref 1]) unless noted.

| Parameter | Value |
|---|---|
| Oral bioavailability | ≥90% (non-saturable absorption; web_retrieved) |
| Tmax (oral) | ~1 hour (≤1 hour at doses ≤300 mg) |
| Protein binding | Negligible (does not bind plasma proteins) |
| Volume of distribution | ~0.5 L/kg (estimated) |
| Half-life (t₁/₂) | 6.3 hours (mean) |
| Steady state | Achieved within 24–48 hours |
| Metabolism | <2% hepatic metabolism; excreted virtually unchanged in urine |
| CYP involvement | None — does not induce or inhibit cytochrome P450 enzymes |
| Elimination | Renal (primary); dose adjustment required for creatinine clearance <60 mL/min (Randinitis et al. 2003 [Ref 16]) |
| Food effect | No clinically relevant effect on amount absorbed |

**Renal dosing:** Total and renal pregabalin clearance are directly proportional (56% and 58%, respectively) to creatinine clearance (CLcr). A 50% dose reduction is recommended for patients with CLcr 30–60 mL/min. Further 50% reduction per each additional 50% decrease in CLcr below 30 mL/min. Pregabalin is highly cleared by hemodialysis; supplemental doses may be needed after each session (Randinitis et al. 2003 [Ref 16]).

**Key distinction from gabapentin:** Pregabalin absorption is non-saturable (dose-proportional and linear across the clinical range), whereas gabapentin absorption is saturable (via a carrier-mediated mechanism). This gives pregabalin more predictable, higher, and dose-proportional plasma concentrations, contributing to greater potency and higher misuse liability (Evoy et al. 2021 [Ref 4]).

**Sustained-release formulation:** Lyrica CR (extended-release), FDA approved 2017, designed for once-daily dosing; shows comparable bioavailability to IR but different PK profile (Moon et al. 2021 [Ref 35 — not formally added but retrieved]).

---

## History

### Discovery and Synthesis

Pregabalin was developed through the collaborative work of **Ryszard Andruszkiewicz** and **Richard Silverman** at **Northwestern University** (Kawczak et al. 2024 [Ref 17]). The synthesis involved derivatives of γ-aminobutyric acid (GABA), with the goal of creating CNS-penetrant GABA analogues with anticonvulsant activity. This work was part of Silverman's broader research program on GABA-related compounds at Northwestern.

**Note on timeline:** Specific published dates for the initial synthesis of pregabalin (S-3-isobutylgaba, also designated CI-1008 in early development) from the primary Northwestern chemistry literature could not be retrieved via API-based literature searches. Published patent and journal records for the exact date of first synthesis are noted as a gap (see below). The broader gabapentinoid class research was active in the late 1980s–early 1990s.

### Regulatory History

- **December 30, 2004:** FDA approved pregabalin (Lyrica®, Pfizer/Viatris) for: adjunctive therapy for partial-onset seizures in adults; management of postherpetic neuralgia; management of neuropathic pain associated with diabetic peripheral neuropathy [Ref 31 — web_retrieved, FDA NDA 021446].
- **2005:** Pregabalin placed on the US market as Lyrica. DEA placed pregabalin in **Schedule V** of the Controlled Substances Act [Ref 33].
- **2007:** Additional FDA approval for fibromyalgia (first FDA-approved drug for this indication).
- **2012 (approximate):** FDA approval for neuropathic pain associated with spinal cord injury.
- **2017:** FDA approval for Lyrica CR (extended-release formulation) for DPN and PHN.
- **2019 (April 1):** UK rescheduled pregabalin from unscheduled to **Class C, Schedule 3** under the Misuse of Drugs Act 1971 (SI 2018/1356) [Ref 32]. This followed a 2016 recommendation from the Advisory Council on the Misuse of Drugs (ACMD) based on escalating drug-related deaths and misuse reports.

**EU/EMA:** Pregabalin is approved in the European Union (as Lyrica) for epilepsy, neuropathic pain, and — notably — **generalized anxiety disorder** (GAD). The GAD indication is not FDA-approved in the US; pregabalin is used off-label for anxiety in the US (Frampton 2014 [Ref 24]).

---

## Subjective Effects

### Clinical Descriptions

Pregabalin's therapeutic effects are mediated by suppression of neuronal excitability in pain-processing and anxiety circuits. In clinical populations, the drug produces:

- **Analgesia:** Significant pain relief in neuropathic conditions (PHN, DPN, fibromyalgia, SCI neuropathic pain) (Crofford et al. 2005 [Ref 3]; Derry et al. 2019 [Ref 22]; Freynhagen et al. 2005 [Ref 19]).
- **Anxiolysis:** Broad-spectrum reduction of psychic and somatic anxiety symptoms in GAD, with rapid onset typically ≤1 week (Frampton 2014 [Ref 24]; Generoso et al. 2017 [Ref 23]).
- **Sleep improvement:** Improved sleep quality is a consistent finding across pain and anxiety trials; pregabalin reduces sleep interference at therapeutic doses (Freynhagen et al. 2005 [Ref 19]; Crofford et al. 2005 [Ref 3]).
- **CNS depression:** At clinical doses, sedation/somnolence (13–29% incidence), dizziness (23–31%), and motor impairment are commonly reported (Ogawa et al. 2012 [Ref 18]).
- **Muscle relaxation:** Mechanism-consistent relaxation effect; spontaneous body sensations reported clinically.

### Recreational Contexts

No controlled laboratory studies on pregabalin's subjective effects in recreational contexts were found via PubMed or OpenAlex searches. Recreational use is characterized primarily through case reports, pharmacovigilance data, and user-report aggregation:

- **Euphoria and disinhibition:** Misusers report pregabalin producing a "high" including euphoria, relaxation, and disinhibition (Schifano 2014 [Ref 21]; Evoy et al. 2021 [Ref 4]).
- **Dose escalation:** Recreational users self-administer at **3–20 times** clinically advisable doses (Schifano 2014 [Ref 21]). Doses in recreational/misuse contexts often exceed 1,000–2,000 mg.
- **Sought effects:** Purposes include eliciting euphoria, enhancing effects of other substances (especially opioids), and self-treating withdrawal or anxiety (Evoy et al. 2021 [Ref 4]).
- **Drug substitution:** Users describe pregabalin as a "valid substitute for most common illicit drugs" at high doses (Schifano 2014 [Ref 21]).
- **Perceptual effects at high doses:** The effects taxonomy in the database includes auditory/visual enhancement and hallucinations. These are consistent with severe CNS depression at extreme doses (anecdotally reported) but are not documented in published controlled studies or case series. They should be treated as community-reported and flagged for review.
- **Tactile euphoria and bodily lightness:** Reported by recreational users; consistent with the anxiolytic and muscle-relaxant profile.

**⚠️ FLAG: Recreational subjective effects not confirmed by controlled studies.** All recreational dose effect characterizations derive from user reports and pharmacovigilance data, not controlled human trials.

---

## Safety & Toxicity

### Acute Toxicity

- **Human LD50:** No published human LD50 data. **⚠️ FLAG: Safety-critical value not confirmed by published source.**
- **Animal data:** No specific published LD50 values retrieved via API searches. The drug is generally described as having low acute toxicity (Frampton 2014 [Ref 24]).
- **Fatal case (Japan, 2024):** Shintani-Ishida et al. (2024 [Ref 6]) report a fatal pregabalin poisoning with femoral blood concentration of **18.5 µg/mL**. The patient was co-prescribed flunitrazepam and zolpidem; pregabalin was determined to play a primary but not independent role in the cause of death. The authors note that fatal pregabalin poisoning is likely under-reported because pregabalin is not routinely included in postmortem drug screens.
- **French addictovigilance data 2010–2019:** 31 gabapentinoid-related deaths (25 pregabalin-associated), with adverse outcomes including coma, dyspnea, convulsion, and cardiac conduction disorders. Virtually all severe/fatal cases involve polydrug use (Tambon et al. 2021 [Ref 15]).

### Common Adverse Effects (Therapeutic Doses)

Data from Ogawa et al. (2012 [Ref 18]) and Freynhagen et al. (2005 [Ref 19]):

| Adverse Effect | Incidence (PHN) | Incidence (DPN) |
|---|---|---|
| Dizziness | 24.9% | 23.0% |
| Somnolence | 15.1% | 13.4% |
| Peripheral edema | 8.8% | 10.3% |
| Weight gain | 3.8% | 7.0% |

- AEs are predominantly mild-to-moderate in severity.
- Dizziness and somnolence typically emerge early in treatment and resolve before treatment ends in most patients.
- **Sexual dysfunction:** Pregabalin induces sexual dysfunctions (erectile dysfunction, decreased libido, ejaculatory disorders) in a dose-related manner, predominantly at doses ≥900 mg/day equivalents (Hamed 2018 [Ref 27]; Bozkurt et al. 2014 [PMID 24612455]).
- **Vision:** Blurred vision, diplopia reported in clinical trials at higher doses (Ogawa et al. 2012 [Ref 18]).
- **Musculoskeletal:** Long-term use may affect calcium homeostasis and musculoskeletal tissue (Reyes Fernandez et al. 2022 [Ref 30]).
- **Testicular toxicity (animal data only):** At very high doses (150–300 mg/kg/day for 90 days in rats), pregabalin decreased testosterone, increased FSH/LH/prolactin, induced genotoxicity via BAX/BCL2 reversal, and increased oxidative stress markers (Taha et al. 2020 [PMID 33051752]). Clinical relevance at human doses unclear; flagged for editorial review.

### Pregnancy

- Patorno et al. (2017 [Ref 25]) assessed first-trimester pregabalin exposure and major congenital malformation risk; results require editorial interpretation. Animal studies show teratogenic potential; human data are limited.
- Singh & Gupta (2018) found teratogenic effects in vivo in animal studies.
- **Pregabalin is generally considered contraindicated in pregnancy** unless benefit clearly outweighs risk; this is reflected in prescribing labels.

### Chronic Toxicity

- The database characterization as "low" acute and chronic toxicity is consistent with the published literature for therapeutic use.
- Chronic high-dose use (misuse/abuse context): hormonal and gonadotoxic effects documented in rats; long-term human effects in misuse populations insufficiently studied.

---

## Harm Reduction

### Key Risk Factors

1. **Polydrug use with opioids:** The most significant harm signal. Gabapentinoids significantly increase opioid-related morbidity and mortality when used concomitantly (Evoy et al. 2021 [Ref 4]; Lyndon et al. 2017 [Ref 11]). The mechanism is additive/synergistic CNS and respiratory depression. This risk is documented in Scottish national mortality data (Torrance et al. 2020 [Ref 13]) and French addictovigilance (Tambon et al. 2021 [Ref 15]).

2. **Benzodiazepine/Z-drug co-use:** Fatal case in Japan involved pregabalin + flunitrazepam + zolpidem; CNS depression is additive (Shintani-Ishida et al. 2024 [Ref 6]). Risk of respiratory depression compounded.

3. **Alcohol:** Additive CNS depression.

4. **Escalating doses:** Recreational escalation to 3–20x therapeutic doses dramatically increases risk of toxicity (Schifano 2014 [Ref 21]).

### Renal Impairment

Pregabalin clearance is directly proportional to creatinine clearance. Standard therapeutic doses can cause accumulation and toxicity in renal impairment. Dose reduction required for CLcr <60 mL/min; significant adjustment for CLcr <30 mL/min (Randinitis et al. 2003 [Ref 16]).

### Withdrawal Management

Do not abruptly discontinue pregabalin; taper gradually. Frampton (2014 [Ref 24]) notes risk of withdrawal symptoms is "generally low when the drug is discontinued gradually (over 1 week)," but case reports document withdrawal even after short-term (2-month) therapeutic use (Ishikawa et al. 2021 [Ref 10]). Diazepam cross-taper has been used in inpatient settings for pregabalin dependence with rebound insomnia (Papanna et al. 2021 [Ref 9]).

### Contraindications (Published)

- Pregnancy (teratogenicity risk)
- Severe renal impairment (dose adjustment required)
- Prior substance use disorder (elevated misuse risk)
- Concurrent CNS depressants, especially opioids (additive respiratory depression)

### Identification

Pregabalin is available as capsules (Lyrica), oral solution, and tablets. Standard reagent tests (Marquis, Mecke, etc.) are unlikely to produce specific color reactions; identification requires chromatographic methods (LC-MS). Pregabalin is not routinely included in standard immunoassay drug screens, meaning co-intoxication may be missed in clinical and forensic settings (Shintani-Ishida et al. 2024 [Ref 6]).

---

## Tolerance & Dependence

### Tolerance

- **Development:** Tolerance to pregabalin's effects develops within several months of continuous use (seed data, no specific published study identified for this exact timeframe).
- **Mechanism:** Downregulation of α₂δ-1 surface expression may contribute to tolerance. Cross-tolerance with benzodiazepines and alcohol is pharmacologically plausible given shared CNS depressant profiles, but not directly confirmed in published human studies.
- The seed data states full tolerance reset at 10.5 days. **⚠️ FLAG: This specific value was not confirmed against a published source during this research cycle.**

### Dependence and Withdrawal

- **Physical dependence:** Documented even at therapeutic doses after as little as **2 months** of use (Ishikawa et al. 2021 [Ref 10]).
- **Withdrawal syndrome:** Includes insomnia (rebound), anxiety, agitation, nausea, diaphoresis, headache, tremor, and in severe cases, seizures (Ishikawa et al. 2021 [Ref 10]; Papanna et al. 2021 [Ref 9]).
- **Risk factors for severe dependence:** Prior substance use disorder (particularly opioids), polysubstance use, psychiatric comorbidity (Gahr et al. 2013 [Ref 8]; Both et al. 2014 [Ref 24 adjacent]).
- **Primary abuse without prior SUD:** Documented in French addictovigilance data; cases of primary abuse without any prior substance use disorder history are confirmed (Tambon et al. 2021 [Ref 15]).

### Misuse Epidemiology

- In France (2010–2019): 816 forged prescriptions (805 pregabalin); pregabalin became the #1 drug in forged prescriptions in 2019 (23.8% of suspicious prescriptions) (Tambon et al. 2021 [Ref 15]).
- In Germany: Cases of pregabalin dependence increasing in medical regulatory database (Gahr et al. 2013 [Ref 8]).
- UK: Prescribing trends show rapid increase pre-rescheduling (Ashworth et al. 2023 [Ref 29]); Scottish national data link gabapentinoid prescribing to drug-related deaths (Torrance et al. 2020 [Ref 13]).
- A decade of European EMA adverse drug reaction data shows rising misuse-related fatalities (Chiappini & Schifano 2016 [Ref 14]).

---

## Interactions

### Opioids (HIGH RISK — SAFETY-CRITICAL)

**Mechanism:** Additive/synergistic CNS and respiratory depression. Pregabalin enhances the potency of mu-opioid receptor agonists in animal models; mechanism at the α₁-VGCC level hypothesized (Hiranita et al. 2025 [PMID 40253987]).

**Evidence:** Gabapentinoids significantly increase opioid-related morbidity and mortality when used concomitantly (Evoy et al. 2021 [Ref 4]; Lyndon et al. 2017 [Ref 11]; Torrance et al. 2020 [Ref 13]). Scottish national data confirm gabapentinoid + opioid co-prescribing is strongly associated with drug-related deaths.

**Specific interaction with oxycodone (from brief):** The brief lists oxycodone interaction as "unknown." Published literature confirms opioid + pregabalin combinations carry additive respiratory depression risk. No oxycodone-specific pregabalin pharmacokinetic interaction study was identified (consistent with pregabalin having no CYP involvement). The interaction is pharmacodynamic (additive CNS/respiratory depression), not pharmacokinetic. **FLAG: Listed as "unknown" in the database; evidence supports reclassifying as "high risk" (pharmacodynamic).**

### Benzodiazepines and Z-Drugs

Additive CNS depression. The Japanese fatal case involved pregabalin + flunitrazepam + zolpidem (Shintani-Ishida et al. 2024 [Ref 6]). Diazepam is used to manage pregabalin withdrawal but must be monitored carefully in polydrug contexts.

### Alcohol

Additive CNS depression expected. No dedicated human pharmacokinetic interaction study was retrieved; the combination is clinically contraindicated based on pharmacodynamic reasoning.

### MDMA

**No published interaction data found.** The brief lists this interaction as "unknown." No pharmacokinetic interaction is expected (pregabalin does not use CYP enzymes). Pharmacodynamic interactions at the level of serotonin syndrome are unlikely (pregabalin has no known serotonergic activity). No published studies, case reports, or controlled data on this combination were identified in PubMed or OpenAlex searches. **FLAG: Interaction with MDMA should remain "unknown" with a note of no evidence for serotonin syndrome risk based on mechanism.**

### Other CNS Depressants

- **Antihistamines, antipsychotics, other anticonvulsants:** Additive CNS depression possible; individual assessment required.
- **No CYP-mediated interactions:** Pregabalin does not inhibit or induce cytochrome P450 enzymes, meaning it is unlikely to alter the plasma concentrations of co-administered drugs metabolized via these pathways (Ben-Menachem 2004 [Ref 1]).

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Date |
|---|---|---|---|
| United States | Controlled substance | Schedule V (DEA) | 2005 [Ref 33] |
| United Kingdom | Controlled substance | Class C, Schedule 3 (Misuse of Drugs Act 1971) | April 1, 2019 [Ref 32] |
| Australia | Prescription only | Schedule 4 (SUSMP) — not a controlled drug | Since 2005 registration |
| European Union | Varies by member state | No uniform EU scheduling | — |
| Norway | Prescription controlled | Prescription Schedule B | — |
| Canada | Prescription required | Not confirmed Schedule V equivalent; prescription required | — |

**FDA-approved indications (US):**
- Adjunctive therapy for partial-onset seizures in adults
- Postherpetic neuralgia
- Neuropathic pain from diabetic peripheral neuropathy
- Fibromyalgia
- Neuropathic pain associated with spinal cord injury

**GAD indication:** Approved in EU and UK; NOT FDA-approved in US (off-label). First-line agent for GAD per World Federation of Societies of Biological Psychiatry alongside SSRIs/SNRIs (Frampton 2014 [Ref 24]).

---

## Clinical Trials

**Key completed pivotal trials (from ClinicalTrials.gov search):**

- **NCT00232141** — Phase 3, Pfizer (Viatris): Pregabalin vs. placebo for HIV neuropathy — COMPLETED
- **NCT01089556** — Phase 3, Eli Lilly: Painful diabetic neuropathy — COMPLETED
- **NCT00843284** — Phase unspecified, Pfizer (Viatris): Symptomatic treatment of neuropathic pain with Lyrica — COMPLETED
- **NCT01603394** — Phase 4, Pfizer: Pilot study of pregabalin and prediction of treatment response in PHN — TERMINATED

**Ongoing/future trials:**
- **NCT06383702** — Phase 3 (CSPC Ouyi Pharmaceutical, China): Pregabalin in painful diabetic peripheral neuropathy — NOT_YET_RECRUITING

**Evidence base summary:**
- Derry et al. (2019 [Ref 22]) Cochrane review is the highest-quality synthesis for neuropathic pain.
- Generoso et al. (2017 [Ref 23]) meta-analysis (8 RCTs, n=2,299) and Slee et al. (2019 [Ref 12]) Lancet network meta-analysis confirm GAD efficacy.
- Crofford et al. (2005 [Ref 3]) remains the landmark fibromyalgia RCT (450 mg/day, 650 citations).
- A meta-epidemiological study (Cheng et al. 2023 [PMID 36662848]) notes that early pregabalin trials showed strong treatment effects for PHN and DPN that have not been replicated in more recent studies, suggesting possible publication bias in early trials.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Values Requiring Editorial Attention

1. **⚠️ Human LD50:** No published human or meaningful animal LD50 data retrieved for pregabalin. Database seed data states acute toxicity = "low" which is consistent with the literature, but no specific lethal dose figure can be cited. Propose retaining "low" characterization with explicit caveat.

2. **⚠️ Oxycodone interaction severity:** Database currently lists as "unknown." Published pharmacovigilance and controlled animal data support reclassifying as high-risk (additive respiratory depression). Editorial review required before changing.

3. **⚠️ Tolerance reset value (10.5 days):** The seed data's specific tolerance reset timeframe of 10.5 days was not confirmed against a published source. No clinical study establishing this precise figure was found. Flag for editorial review.

4. **⚠️ Recreational dose subjective effects:** Effects taxonomy entries including visual/auditory hallucinations, tracers, color enhancement, etc. are not confirmed by controlled studies or case reports in published literature. These appear to derive from community user reports. Flag as user-report-only; generation agent should note absence of published evidence.

### Data Gaps (No Published Sources Found)

5. **Rectal ROA pharmacokinetics:** The database contains dosing and duration data for rectal administration. No published pharmacokinetic studies for rectal pregabalin administration were found in PubMed or OpenAlex searches. This is community/informal data only. The rectal route is not a licensed route of administration. Duration and dose data for this ROA should be clearly labeled as lacking published supporting evidence.

6. **MDMA interaction:** No published data found. Based on mechanism (no serotonergic activity, no CYP involvement), serotonin syndrome risk appears unlikely but cannot be excluded from first principles.

7. **Pregabalin synthesis date / first publication:** The precise date and primary publication describing the initial synthesis of pregabalin by Silverman/Andruszkiewicz at Northwestern could not be retrieved through PubMed/OpenAlex keyword searches. The Kawczak et al. (2024) review provides attribution but not specific dates. The Northwestern University patent (US5563175 or similar) should be consulted for primary authorship/date.

8. **Dependence data in the brief:** The seed data "Dependence data" field is blank. Based on research, the dependence profile is now well-characterized (physical dependence at therapeutic doses within 2 months; withdrawal syndrome; abuse potential documented across multiple countries).

9. **Contraindications in the brief:** The seed data "Contraindications" field is blank. Confirmed contraindications from literature include: pregnancy, severe renal impairment (dose adjust), concurrent opioids/CNS depressants, prior SUD.

### Discrepancies Between Seed Data and Published Sources

10. **Pharmacological class:** The seed data lists "Alpha-2-delta voltage-gated calcium channel blocker." More accurately, pregabalin is an **α₂δ subunit ligand** (binding to the auxiliary subunit, not blocking the channel pore directly). The distinction is important: it reduces calcium influx indirectly by impairing α₂δ-1 trafficking to presynaptic membranes, not by directly blocking the channel. The brief's characterization is an acceptable simplification but a more precise term would be "α₂δ voltage-gated calcium channel subunit ligand."

11. **"No direct GABA effects" vs. "GABA analogue":** The brief lists "Amino acid compound" and "Gabapentinoid" for chemical class, which is accurate. However, generation agents should be explicitly warned that despite the structural name ("GABA analogue"), pregabalin has **no demonstrated effects on GABA receptors or GABAergic mechanisms** (Ben-Menachem 2004 [Ref 1]).

12. **Canada legal status:** Not confirmed to Schedule V equivalent. Research found no specific Canadian scheduling classification during this cycle. Flag for jurisdictional research.

---

*Research conducted 2026-04-27. Citation count: 34 verified citations in registry.*